<DOC>
	<DOCNO>NCT01994382</DOCNO>
	<brief_summary>This study identify high dose , assess safety , cerdulatinib ( PRT062070 ) may give patient relapsed/refractory chronic lymphocytic leukemia non-hodgkin lymphoma</brief_summary>
	<brief_title>Phase 1/2A Dose Escalation Study CLL , SLL NHL</brief_title>
	<detailed_description>This open-label , Phase 1/2a , multi dose , multi-center trial orally administer cerdulatinib assess safety , tolerability PK parameter conduct 2 phase : - Phase 1 : Dose-escalation portion , 52 patient enrolled receive single-agent cerdulatinib assign dose level start 15 mg QD , administer increase dos MTD/MAD identify . - Phase 2a : Consisting 6 planned cohort 40 patient cancer type . Five cohort receive single agent cerdulatinib start dose 35 mg BID 28 day escalate 40 mg BID absence Grade 3 high toxicity . Cohort 2 receives cerdulatinib plus rituximab IV 375 mg/m2 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Phase 1 Specific Patient least 18yrs age histologically confirm CLL/SLL Bcell NonHodgkin lymphoma ( DLBCL , FL , MCL , MZL , lymphoplasmacytic lymphoma ) . Phase 2a Inclusion Histological evidence : FL Grade 13A/iNHL , relapse refractory disease ( iNHL include LPL/WM , MZL ) ; aNHL , define DLBCL , FL Grade 3B , MCL , transform NHL relapse disease ; CLL/SLL , PTCL , CTCL ( MF/SS ) relapse refractory . Received BCR and/or BCL2 inhibitor intolerant relapsed/refractory disease afterwards . Prior treatment lymphoid malignancy progressive /refractory disease ≥ 1 prior regimen ( min 2 cycle ) antibody conjugate , cytotoxic chemotherapy , TKI alone combination . Submission formalinfixed block 10 slide lymph node biopsy able . Measureable disease define : ≥ 1 lesion ≥ 1.5 cm single dimension via CT , CT/PET nodal mass lesion ; Quantifiable circulate tumor cell ; Waldenström 's macroglobulinemia presence IgM l &gt; 2X ULN ; For CTCL : mSWAT &gt; 0 Ability provide diagnostic report General Inclusion ECOG Score 0 1 . Hematologic ANC &gt; 1000/uL platelet &gt; 75,000/uL , Serum creatinine &lt; 1.5 ULN calculate CrCl &gt; 60 mL/min Bilirubin &lt; 20.0mg/dL ( Gilberts &lt; 2.5 mg/dL ) AST/AST &lt; 2.5 ULN Richter 's syndrome , Burkitt 's lymphoma , Burkittlike Lymphoma ( transform DLBCL Follicular NHL eligible ) . Prior transplant stem cell infusion 90 day active graftversushost treatment within 8 week Day 1 . Prior therapy SYK inhibitor . Chronic treatment strong CYP3A4 inhibitor/ inducer , acid reduce agent , Proton pump inhibitor Known lymphomatous involvement CNS . Persistent , unresolved NCI CTCAE v4.0 ≥ Grade 2 , previous drugrelated toxicity ( except alopecia , erectile impotence , hot flash , libido , neuropathy ) . Prior monoclonal antibody , radioimmunoconjugate , antibody drug conjugate , phototherapy , radiotherapy , chemotherapy , immunotherapy , immunosuppressive therapy , test agent within 3 week alemtuzumab 8 week Day 1 . For CTCL : ( TSEBT ) within 12 week , initiation topical steroid , nitrogen mustard , topical retinoid within 2 week . ( Stable topical ≥ 4 week prior Day 1 allow ) . Known carrier infection HIV/Hep B C. HCV ab+ must PCR . HBV ab+ must HBsAg undetectable DNA Active infection require systemic treatment , Significant GI disease , previous major gastric/bowel surgery , difficulty swallow malabsorption syndrome . Major surgery within 4 week Previous malignancy within 2 yr . unless relapse risk small ( &lt; 5 % ) . Current use systemic steroid &gt; 20 mg QD prednisone ( equivalent ) Breastfeeding pregnant ( intention become ) females participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphocytic</keyword>
	<keyword>Chronic</keyword>
	<keyword>B Cell</keyword>
</DOC>